Inhibition of amyloid formation of the Nucleoprotein of SARS-CoV-2.
Journal
bioRxiv : the preprint server for biology
Titre abrégé: bioRxiv
Pays: United States
ID NLM: 101680187
Informations de publication
Date de publication:
18 Mar 2021
18 Mar 2021
Historique:
pubmed:
11
3
2021
medline:
11
3
2021
entrez:
10
3
2021
Statut:
epublish
Résumé
The SARS-CoV-2 Nucleoprotein (NCAP) functions in RNA packaging during viral replication and assembly. Computational analysis of its amino acid sequence reveals a central low-complexity domain (LCD) having sequence features akin to LCDs in other proteins known to function in liquid-liquid phase separation. Here we show that in the presence of viral RNA, NCAP, and also its LCD segment alone, form amyloid-like fibrils when undergoing liquid-liquid phase separation. Within the LCD we identified three 6-residue segments that drive amyloid fibril formation. We determined atomic structures for fibrils formed by each of the three identified segments. These structures informed our design of peptide inhibitors of NCAP fibril formation and liquid-liquid phase separation, suggesting a therapeutic route for Covid-19. Atomic structures of amyloid-driving peptide segments from SARS-CoV-2 Nucleoprotein inform the development of Covid-19 therapeutics.
Identifiants
pubmed: 33688654
doi: 10.1101/2021.03.05.434000
pmc: PMC7941625
pii:
doi:
Types de publication
Preprint
Langues
eng
Subventions
Organisme : NIGMS NIH HHS
ID : R01 GM123126
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG054022
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007185
Pays : United States